Bold claim: Basic neuroscience is quietly reshaping medicine, turning lab insights into real drugs that help millions. But here’s where it gets controversial: you can’t judge progress by a single miracle drug alone. The full story is a long arc of discoveries, each building on careful experimentation and patient observation.
Despite decades of foundational work, many neurological and psychiatric conditions still lack universally effective treatments. It’s a common gripe among researchers that “Basic neuroscience hasn’t produced new drugs.” That view has some bite, since many current medicines originated from ancient use or chance findings. Opium’s thousand-year history as a pain reliever led to morphine and other opioids, and ketamine began as an anesthetic before later revealing antidepressant effects at low doses.
Yet this view misses a growing ledger of drugs rooted in fundamental science. Zuranolone for postpartum depression, suzetrigine for pain, and the gepants used for migraines didn’t emerge from serendipity or folklore; they grew out of disciplined, long-running lab research. These examples demonstrate that basic neuroscience can yield genuinely new medicines, a point worth emphasizing as public money for research faces pressures and policy debates intensify about funding and animal-model use.
Consider zuranolone’s path. It mirrors a deeper principle: a natural brain steroid, allopregnanolone, modulates brain activity not by steroid receptors, but by acting on GABA receptors, dampening neuronal excitability. In the late 1990s, scientists found allopregnanolone surges in the rat brain during pregnancy, sometimes tripling normal levels, with a steep drop just before birth. This observation suggested a therapeutic strategy: restore those levels to counter postpartum depression. Clinical trials validated the idea, and in 2019 the FDA approved brexanolone (Zulresso), an infusion of a synthetic allopregnanolone, as the first drug specifically for postpartum depression. An oral counterpart followed two years later as zuranolone (Zurzuvae).
A parallel non-opioid breakthrough in pain came from studying dorsal root ganglion neurons and their action potentials, which rely on sodium channels. In a 1996 rat study, researchers identified an additional sodium channel, Nav1.8, largely confined to the dorsal root ganglion. Without Nav1.8, these sensory neurons struggle to sustain firing, offering a target to interrupt pain transmission without dampening brain activity. Because Nav1.8 operates via a different mechanism than opioid receptors, blocking it avoids opioid-type addiction risk. Building on this, Vertex developed suzetrigine (Journavx), a small molecule that selectively inhibits Nav1.8 for pain relief, approved by the FDA as a short-term treatment for moderate to severe pain.
Similarly, a peptide uncovered in the 1990s—calcitonin gene-related peptide (CGRP)—inspired a new migraine therapy class. CGRP is abundantly produced by rat trigeminal neurons; one branch of these neurons interfaces with brain arteries, and when CGRP is released, it can stretch vessel walls and amplify pain signaling. This discovery led to the first CGRP receptor blockers, ubrogepant (Ubrelvy) in 2019, followed by anti-CGRP monoclonal antibodies for migraine prevention. Unlike older treatments, these therapies target a distinct mechanism and tend to offer safer, effective options for patients who don’t respond to traditional drugs.
Other career-defining findings show how neurobiology informs drug design. For instance, studying how hypothalamic neurons regulate body temperature yielded fezolinetant (Veozah) to reduce menopausal hot flashes and night sweats. Targeting the N-type calcium channel produced ziconotide (Prialt) for chronic pain, and recognizing dopamine deficiency in Parkinson’s disease gave rise to L-DOPA, still a mainstay today. Beyond new mechanisms, basic research has also pushed for better brain-targeted distribution and reduced side effects.
Why, given decades of inquiry, aren’t there more such success stories? The answer is nuanced. Drug development faces high costs, potential trial design flaws, and side effects that derail progress. But translation can improve when we rethink how we pursue discovery: deeper biology, smarter targets, and wiser use of models. CGRP’s emergence shows how a single target can unlock whole classes of therapies, while sometimes the best clues come from simple measurements—like allopregnanolone fluctuations during pregnancy—rather than fully mapping the disease’s complex causes.
Sometimes, you don’t need to solve an entire disorder to intervene effectively; identifying the right leverage point can be enough, as Nav1.8 targeting demonstrates for pain. And conditions with tighter definitions, such as postpartum depression, can offer clearer entry points than broader, more heterogeneous disorders like major depression.
Another takeaway is timing. These breakthroughs began decades ago in the 1980s and 1990s, with real patient benefits only arriving recently. The pace of discovery has accelerated in the last twenty years, and I believe we’ll see more basic science translate into medicines. Achieving that promise depends on continued, stable public investment in basic research, because those early discoveries are the seeds from which future therapies grow.
So, what’s the core takeaway? Basic neuroscience is not just academic curiosity—it’s the wellspring of tomorrow’s medicines. But the conversation should be honest about challenges, celebrate the successes, and encourage ongoing support for foundational research. How far should we go in funding basic science when the payoff is years away, and how do we balance that with faster, translational goals? Share your thoughts in the comments: do these examples strengthen the case for basic research, or do they reveal the limits of our current development pathways? And if you could design the next big target from basic neuroscience findings, what area would you choose? Let’s discuss.
